Cytori Therapeutics (CYTX) Announces Publication of Cell Therapy Data for Combined Radiation, Thermal Injury
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced the publication of preclinical safety and efficacy study data using Cytori Cell Therapy for combined radiation and thermal injury. This preliminary study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.
The paper, entitled “Development of a Combined Radiation and Full Thickness Burn Injury Minipig Model to Study the Effects of Uncultured Adipose-Derived Regenerative Cell Therapy in Wound Healing,” was published in the International Journal of Radiation Biology and is now available online.
The paper reports that injection of Cytori Cell Therapy by either local or intravenous administration led to improvement of healing of full thickness burns that were compromised by concomitant exposure to sub-lethal, marrow-damaging total body irradiation. Treated wounds exhibited 3.5-fold greater re-epithelialization at two weeks post-treatment (relative to control), increase in blood vessel density by an average of 67%, and an increase in matrix (collagen) deposition of 30%. Similar results were observed when the Therapy was injected directly into the wound or by intravenous administration. Local and intravenous Therapy delivery were well tolerated and no serious side effects related to body weight, loss of appetite, infection, activity, or complete blood counts was observed over the course of the study.
“These preclinical data support the clinical rationale for the investigational use of topical or intravenous administration of Cytori Cell Therapy in burn patients,” said Dr. John Fraser, Cytori’s Chief Scientist. “We are leveraging this data in a forthcoming U.S. FDA investigational device exemption (IDE) application for the RELIEF Phase I clinical trial to assess the safety and feasibility of the intravenously administered Cytori Cell Therapy as a novel thermal burn countermeasure.”
The current healthcare system is ill-prepared for large numbers of patients requiring simultaneous treatment. Current standard of care consists of dressings, skin grafts, and skin substitutes. Despite these treatments, patients with severe burns commonly suffer from prolonged pain, aggressive scarring, skin contracture, and reduced range of motion. Autologous Cell Therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring and also can be deployed in a cost-effective manner, even in mass casualty situations.
In a mass casualty event, the Government Accountability Office estimates that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event. Therefore, the Cytori Cell Therapy approach represents a novel potential medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and help improve casualty care.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PICO Holdings (PICO) Announces Leadership, Governance Changes; Terminates Central Square Agreement
- MyoKardia (MYOK) Receives $25M Milestone Related to MYK-491 Development (SNY)
- Amgen (AMGN), Allergan (AGN) Announce Submission of ABP 215 MAA to EMA
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!